{
    "clinical_study": {
        "@rank": "82331", 
        "arm_group": {
            "arm_group_label": "mesenchymal stem cells", 
            "arm_group_type": "Experimental", 
            "description": "Stem cells implantation Patients with severe coronary artery disease with ischemic cardiomyopathy managed with intramyocardial administration of allogeneic mesenchymal stem cells."
        }, 
        "brief_summary": {
            "textblock": "The aim of the present study is to investigate safety and efficacy of intramyocardial\n      implantation of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy ."
        }, 
        "brief_title": "Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Cardiomyopathy", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Cardiomyopathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "Coronary artery disease (CAD) is a common disorder that can lead to heart failure. Not all\n      people with CAD are eligible for today's standard treatments. One new treatment approach\n      uses umbilical cord blood derived mesenchymal stem cells\u2014specialized cells capable of\n      developing into other types of cells\u2014to stimulate growth of new blood vessels for the heart.\n      The aim of the present study is to investigate safety and efficacy of intramyocardial\n      implantation of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy ."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age from 30 to 80 years\n\n          2. ischemic cardiomyopathy\n\n          3. Left ventricular infarction area seriously low movement to no movement\n\n          4. The low whole left ventricular systolic function (LVEF 45% or less)\n\n          5. Have line or quasi coronary interventional treatment\n\n          6. Willing to accept patients with follow-up evaluation\n\n          7. Have signed informed consent form approved by the ethics committee\n\n        Exclusion Criteria:\n\n          1. Non elevation between S-wave and T-wave in patients with acute myocardial infarction\n\n          2. No function damage in patients with acute myocardial infarction\n\n          3. Acute myocardial infarction complicated with left ventricular aneurysm intends to do\n             surgery\n\n          4. Complications of acute myocardial infarction with other machines    (including:\n             ventricular septal perforation, papillary muscle rupture, etc.)\n\n          5. Acute infectious diseases\n\n          6. Blood system diseases, such as thrombocytopenia, severe anemia, leukemia, etc\n\n          7. Severe renal disease, creatinine clearance < 36 ml/min, serum creatinine > 265 umol/L\n\n          8. Laboratory tests suggest abnormal liver function, glutamate-pyruvate transaminase\n             (ALT) > 4 times the upper limit of normal\n\n          9. Unstable cerebral lesions\n\n         10. malignant tumor\n\n         11. Cognitive dysfunction and dementia patients, patients with severe mental illness\n\n         12. Patients with severe physical disabilities can't regular follow-up\n\n         13. Other serious uncontrolled system disease\n\n         14. To prepare or have the pregnancy women patients\n\n         15. Have a percutaneous coronary intervention contraindications: high-risk patients, such\n             as the digestive tract, and intracranial hemorrhage or contrast allergy\n\n         16. Cannot use the test dose atorvastatin\n\n         17. Is not completed in accordance with the requirements for test the timing of the\n             magnetic resonance imaging (MRI), PET, SPECT, follow-up testing (e.g., patients with\n             implanted pacemakers or artificial joint)\n\n         18. Patients unable or unwilling to sign a consent form"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946048", 
            "org_study_id": "12276102D-Cardiac Disease"
        }, 
        "intervention": {
            "arm_group_label": "mesenchymal stem cells", 
            "description": "Procedure: Selected patients were randomly divided into a cell therapy group and a control group.\nUmbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million.", 
            "intervention_name": "mesenchymal stem cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shijiazhuang", 
                    "country": "China", 
                    "state": "Hebei", 
                    "zip": "050000"
                }, 
                "name": "the First Hospital of Hebei Medical University"
            }, 
            "status": "Active, not recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Efficacy Investigation of Patients With Ischemic Cardiomyopathy by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells", 
        "overall_official": [
            {
                "affiliation": "Hebei Medical University First Hospital", 
                "last_name": "Baoyong Yan, Doctor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Hebei Medical University First Hospital", 
                "last_name": "Gang Liu, Doctor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Hebei Medical University First Hospital", 
                "last_name": "Guoping Ma, Master", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hebei Medical University First Hospital", 
                "last_name": "Jun Zhang, Master", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "China: Ethics Committee", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Left ventricular ejection fraction\uff1a Change in left ventricular ejection fraction assessed with echocardiography after intramyocardial implantation of allogeneic mesenchymal stem cells.", 
            "measure": "The examination of heart function", 
            "safety_issue": "No", 
            "time_frame": "Post cell transplantation: 1, 3, 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946048"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hebei Medical University", 
            "investigator_full_name": "Quanhai Li", 
            "investigator_title": "Director of Cell Thearpy Center, the First Hospital of HeibeiMU", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "all-cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "Post cell transplantation: one year"
            }, 
            {
                "measure": "all-cause morbidity", 
                "safety_issue": "No", 
                "time_frame": "Post cell transplantation: one year"
            }, 
            {
                "measure": "major adverse cardiac and cerebrovascular events", 
                "safety_issue": "No", 
                "time_frame": "Post cell transplantation: one year"
            }
        ], 
        "source": "Hebei Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hebei Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}